Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SPR Therapeutics
Sandoz Eyes First-To-Market US Opportunities With Adalvo Deal
Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.
Multiple Agreements At Adalvo As Company Expects To File 30 DCPs This Year
Alvo group B2B unit Adalvo expects to file 30 decentralized procedures in Europe over the coming year as it expands its partnerships with Frontier Biopharma, Zentiva and Stada.
Hikma And Adalvo Ally On Nasal Spray For MENA
Hikma and Adalvo have struck a licensing deal that will see Hikma commercialize a “high value” nasal spray treatment for allergic rhinitis in the MENA region.
NANS 2020: SPR Therapeutics' Nerve Stimulation System Provides 12-Month Pain Relief After 60-Day Treatment
SPR Therapeutics said its SPRINT neurostimulation technology achieved a 63% reduction in average pain intensity in patients with chronic low back pain.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.